[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627164":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":67,"collaborators":69,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":24,"eligibilityCriteria":81,"healthyVolunteers":78,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":24,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":44,"whyStopped":24,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"University of Central Florida","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Medilepsy® Chatbot AI-Enhanced","EXPERIMENTAL","Participants in the intervention group will use the AI-personalized version of the Medilepsy® app.",[13],"Other: Medilepsy® Chatbot AI-Enhanced",{"label":15,"type":16,"description":17,"interventionNames":18},"Medilepsy® Chatbot Standard","ACTIVE_COMPARATOR","Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality.",[19],"Other: Medilepsy® Chatbot Standard",[21,25],{"type":6,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"Participants in the intervention group will use the AI-personalized version of the Medilepsy® app, which includes a Smart Chatbot that delivers interactive support based on user-entered data. The chatbot offers personalized prompts, relevant topic suggestions, and adaptive educational content to support epilepsy self-management.",[9],null,{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality. This version includes static prompts and general educational links but does not provide personalized feedback or adaptive interaction.",[15],[29],{"name":30,"affiliation":5,"role":31},"Michelle Tall, PhD, RN, FAES","PRINCIPAL_INVESTIGATOR",[33,37],{"name":30,"role":34,"phone":35,"phoneExt":24,"email":36},"CONTACT","4077970555","Michelle.Tall@UCF.edu",{"name":38,"role":34,"phone":39,"phoneExt":24,"email":40},"Amoy Fraser, PhD, CCRP, PMP","4072668742","Amoy.Fraser@UCF.edu",[42,59],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Orlando Health Arnold Palmer Hospital","RECRUITING","Orlando","Florida","32806","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-81.37924,28.53834,{"lat":54,"lon":53},[57],{"name":30,"role":34,"phone":58,"phoneExt":24,"email":36},"4077970100",{"facility":60,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Orlando Health Orlando Regional Medical Center",{"type":51,"coordinates":62},[53,54],{"lat":54,"lon":53},[65,66],{"name":30,"role":34,"phone":58,"phoneExt":24,"email":36},{"name":30,"role":31,"phone":24,"phoneExt":24,"email":24},{"type":68,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[70,72,74],{"name":71,"class":6},"American Epilepsy Society",{"name":73,"class":6},"Orlando Regional Medical Center",{"name":43,"class":75},"UNKNOWN","100627164","ai-based-mobile-intervention-on-medication-non-adherence-and-transition-100627164",false,"NCT07445074","AI-Based Mobile Intervention on Medication Non-Adherence and Transition","Inclusion Criteria:\n\n* Diagnosed with epilepsy\n* Currently prescribed anti-seizure medicine (ASMs)\n* Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)\n* Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study\n* Are between 18-24 years old and able to provide informed consent\n* Able to read, speak, and write in English\n* Resides in Florida\n* Receive outpatient medical services\n\nExclusion Criteria:\n\n* They do not own a mobile device with internet access.\n* They have a history of severe intellectual disability.\n* They are unable to operate a mobile device (keyboard or touchscreen).\n* Reside in an in-patient setting.\n* Adults unable to consent.\n* Pregnant women (excluded because pregnancy is not relevant to the study focus).\n* Prisoners.","ALL","14 Years","24 Years",{"count":86,"type":87},200,"ESTIMATED","INTERVENTIONAL",[90],"NA","This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA.\n\nOutcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.",[93,94],"Epilepsy","Seizure",[96,97,98,99,100,93,101,102,103,104,105],"Adherence","Anti-seizure medications","Artificial Intelligence","Chat-bot","Chronic disease","Mobile Applications","Self-management","Seizures","Transition","Underserved","2026-05-27",{"date":108,"type":109},"2026-05-29","ACTUAL",{"date":111,"type":87},"2026-05",{"date":113,"type":87},"2026-12",{"name":5,"class":6},2]